Accéder au contenu
Merck

Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.

Antimicrobial agents and chemotherapy (2007-08-08)
Sonia K Morgan-Linnell, Lynn Zechiedrich
RÉSUMÉ

In defined, isogenic strains, at least three mutations, two of which must be in gyrA, were required to exceed the CLSI breakpoint for fluoroquinolone resistance. Strains with double mutations in both gyrA and parC had even higher MICs of fluoroquinolones than strains with totals of three mutations.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)
Sigma-Aldrich
Sparfloxacine, ≥98.0% (HPLC)
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Norfloxacin, VETRANAL®, analytical standard